Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: March 2009
-
By Donald Zuhn — BIO Seeks Improvements to Patent Reform Legislation Following Tuesday's hearing on patent reform, the Biotechnology Industry Organization (BIO) issued a press release urging the Senate Judiciary Committee to make improvements to its new patent reform bill (S. 515). The organization's written testimony, which was submitted to the Committee on Tuesday,…
-
By Donald Zuhn — It appears that Representative Henry Waxman (D-CA) (at right) will be the first to introduce a follow-on biologics bill in the 111th Congress. According to a Reuters report, Rep. Waxman has initiated a bipartisan effort to create a follow-on biologics regulatory pathway in the United States. Rep. Waxman, who was…
-
By Kevin E. Noonan — In all the understandable excitement surrounding President Obama's lifting of the Bush Administration's ban on federal funding for embryonic stem cell research, his broader message may have gotten lost. Overturning the stem cell ban is just a part of a return to the tradition, the guiding principle in Western…
-
By Donald Zuhn — For almost two hours this morning, the Senate Judiciary Committee heard testimony regarding its efforts to reform U.S. patent law. Not surprisingly, much of the discussion at the hearing focused on Section 4 of the Senate patent reform bill (S. 515), which concerns damages. The damages provision of S. 515…
-
By Suresh Pillai — Final Judgment Granted to Applera in Dispute with Enzo On March 5, the U.S. District Court for the District of Connecticut, upon the order of the Court of Appeals for the Federal Circuit (see "Biotech/Pharma Docket," March 2, 2009), reopened the patent litigation suit between Applera (based in Foster City,…
-
By Christopher P. Singer — In a Federal Register Notice (74 Fed. Reg. 10036) published on Monday, March 9, the U.S. Patent and Trademark Office announced that it is extending the deadline for submitting written comments regarding issues raised at last month's roundtable discussion on deferred examination, or any issue relating to deferral of…
-
By Kevin E. Noonan — The Court of Appeals for the Federal Circuit occupies a unique place in the Federal appellate system. Like the D.C. Circuit and unlike the other circuits, it is not regional and its jurisdiction is not limited to Federal District Courts in a particular geographical area. Instead, its subject matter…
-
By Donald Zuhn — The new year has witnessed yet another blockbuster biotech/pharma deal. On the heels of Pfizer's $68 billion acquisition of Wyeth (see "Pfizer Expected to Announce Wyeth Acquisition on Monday") in January, Merck & Co., Inc. and Schering-Plough Corp. announced today that their Boards of Directors had unanimously approved a definitive…
-
By Donald Zuhn — The New York Times reported late last week that President Obama will satisfy one of his campaign pledges on Monday when he reverses limits imposed by the Bush administration on embryonic stem cell research. In August of 2001, the Bush administration ordered that federal research be limited to lines of…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Genzyme Corp. v. Lupin Ltd. et al.1:09-cv-00147; filed March 5, 2009 in the District Court of Delaware Infringement of U.S. Patent Nos.…
Patent Docs 